Logistics of human oral and cartilage tissues, added value to regenerative medicine
TOKYO, March 03, 2022–(BUSINESS WIRE)–A highly effective human cadaver corneal-donor transport method, developed by Japanese scientists, could increase the availability of donated eyes for millions of patients with corneal blindness awaiting corneal transplant to restore vision. The OPTRACT method, which better preserves human oral tissue and cartilage during transport between hospitals and laboratories, reverses cellular aging, in addition to having obtained a Japanese patent for the functional improvement of immune cells under microgravity. These achievements herald a futuristic strategy for assessing the implications of interstellar environments on human cells aboard a zero-gravity space station, which, if it defies aging-related damage, may provide solutions to the frailty of aging, say Researchers.
This press release is multimedia. View the full press release here: https://www.businesswire.com/news/home/20220302006156/en/
Depositing cells aboard a space station in weightlessness or microgravity from other planets or interstellar space, in which, if the aging implications or cell damage could be mitigated, cell storage human strains for a certain duration, with appropriate gravitational forces then re-infusion, could yield restoration of youth. Achievements of cell and tissue transport based on the OPTRACT method between hospitals and laboratories for regenerative medicine – cell therapy applications, corneal transport of human cadavers between destinations and cryopreservation of stem cells; several published by Japanese scientists and granted patents, paved the way for these futuristic research strategies for space-age anti-aging solutions. In vitro culture based on the OPTRACT method has made it possible to reverse the senescence of human chondrocytes in the laboratory, using exclusive tissue engineering techniques. (Graphic: Business Wire)
Cell therapies in regenerative medicine involve the harvesting of tissues in hospitals, transportation to cell processing facilities, isolation, cell culture, and storage for varying lengths of time until transplantation to patients.
Scientists with interdisciplinary expertise have developed the following innovative solutions, using chemically engineered polymer scaffolds:
Human cadaver donor corneal transport with better preservation of corneal endothelial density: https://doi.org/10.1007/s10529-021-03116-y
Storage and transportation of human oral mucosa for the treatment of male urethral stricture: https://doi.org/10.1089/bio.2021.0079
Cartilage transport for ACI & MACI cell therapies, to treat knee joint damage: https://doi.org/10.1016/j.jor.2022.01.007
Corneal endothelial logistics without cold chain (https://pubmed.ncbi.nlm.nih.gov/24008800/) and treatment of bullous keratopathy: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5840311/
Microgravity, Enhancing Nitric Oxide, an immune cell weapon to destroy cancer: Japanese patent: 6757578/2020
Cryopreservation of stem cells from bone marrow and cord blood: Japanese patent: 6373241/2018
Having proven maintenance of phenotype and improved viability of human cells and tissues at varying temperatures outside the body, enhancement of natural killer cells and reversal of cellular senescence in the laboratory (https://doi .org/10.1038/s41598-021-93607-9), they plan to study cell biology and epigenetics in the weightless environment of a space station, to which cells could be transported and stored, s ‘they have been proven to attenuate senescence, which could give clues to anti-aging solutions, they propose.
“The time has come for a dream project of cell deposition aboard a space station, with like-minded institutes, that could herald the birth of a new space-age anti-aging medicine,” commented Dr. Shojiro Katoh, President of Edogawa Hospital, with beaming hope as his collaborators appreciated a healthy ecosystem in Japan, enabling the development of new solutions, its synergy with GN Corp’s interdisciplinary expertise and global network and the support of JBM Inc.
See the source version on businesswire.com: https://www.businesswire.com/news/home/20220302006156/en/
Samuel JK Abraham